The efficacy of the combination of percutaneous transhepatic biliary drainage and $^{125}$I stranded seeds for malignant bile duct obstruction treatment

Shuangxi Li, BS, Baohua Li, MS, Lai Li, MS, Xujun Yang, MS, Fangyu Xu, BS, Wenhui Wang, PhD
Interventional Department, The First Hospital of Lanzhou University, Lanzhou, Gansu, China

Abstract

Purpose: To investigate the efficacy of percutaneous transhepatic biliary drainage (PTBD) combined with iodine-125 ($^{125}$I) stranded seeds for the treatment of malignant bile duct obstruction (MBO).

Material and methods: A retrospective study was performed on 58 consecutive MBO patients. Twenty patients underwent PTBD combined with $^{125}$I stranded seeds (group A). Thirty-eight patients underwent percutaneous transhepatic biliary drainage (group B). Total bilirubin, direct bilirubin, and indirect bilirubin levels were compared preoperatively, 1-week, 1-month, and 3-months post-operatively. Carbohydrate antigen 19-9 (CA19-9), cancer antigen 125 (CA125), and carcino-embryonic antigen (CEA) levels were compared at preoperative and 3-month post-operative stages. The time free from biliary obstruction and survival times were compared.

Results: The differences in total bilirubin, direct bilirubin, and indirect bilirubin levels between the two groups were not significant preoperatively ($p = 0.857$, $p = 0.719$, and $p = 0.870$), and 1-week post-operatively ($p = 0.259$, $p = 0.395$, and $p = 0.145$). However, 1-month ($p = 0.012$, $p = 0.005$, and $p = 0.049$) and 3-months post-operatively ($p < 0.001$, $p = 0.001$, and $p = 0.001$), group A was lower than group B. Differences in CA19-9, CA125, and CEA levels between the two groups were not significant preoperatively ($p = 0.229$, $p = 0.116$, and $p = 0.273$) and 3-months post-operatively ($p = 0.159$, $p = 0.342$, and $p = 0.306$). The median biliary obstruction free time was 7.0 months for group A and 5.0 months for group B ($p < 0.001$). The median survival time was 9.0 months for group A and 6.0 months for group B ($p = 0.001$).

Conclusions: PTBD combined with $^{125}$I stranded seeds seem to reduce bilirubin levels and prevents biliary obstruction, promoting survival.

Key words: percutaneous transhepatic biliary drainage, iodine-125, malignant bile duct obstruction, survival.

Purpose

Obstructive jaundice can arise from both malignant and benign sources, with the primary causes of malignant bile duct obstruction (MBO) being cholangiocarcinoma, gall bladder carcinoma, pancreatic adenocarcinoma, metastases of other tumors, or common bile duct (CBD) compression by proximal lymph nodes [1]. If not treated in a timely and effective manner, the obstruction can quickly lead to deterioration of liver, renal function, and blood coagulation, endangering patient’s life [2]. Resection is the most efficacious treatment option; however, many patients are not right candidates for this surgical procedure owing to their advanced disease state [3,4]. Adequate biliary drainage was the first selective palliative treatment method developed for patients with MBO, and some guidelines recommend the percutaneous approach over endoscopic retrograde cholangiography (ERC) for Bismuth type 3 and 4 hilar strictures [5]. However, this treatment has no therapeutic effect on tumors [6,7]. In recent years, intracavitary brachytherapy has been widely applied clinically, especially in patients with MBO [8]. This study investigated whether percutaneous transhepatic biliary drainage (PTBD) combined with iodine-125 ($^{125}$I) stranded seeds can achieve good clinical effect.

Material and methods

Patients

The study protocol was approved by an institutional ethical committee (LDYYLL2018-115) and an informed consent was obtained from every patient before enrollment. A retrospective analysis was performed using the institutional database from May 2014 to May 2016 and was accessed to identify patients with MBO who underwent PTBD combined with $^{125}$I stranded seeds or PTBD. Patients’ inclusion criteria involved clinically or histo-
pathologically confirmed malignant obstructive jaundice and with symptoms of jaundice, pruritus, cholangitis, or pain. Computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound were conducted in all patients prior to the interventional procedure. Patients were of normal consciousness, cooperative, with the Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3. Exclusion criteria included biliary tract strictures that were uncrossable, perforation of ducts within the biliary tree, ECOG performance of 4, contrast medium allergies, renal dysfunction, previous surgical treatment, or were non-cooperative with treatment. Chemotherapy was not an exclusion criterion for enrollment.

Finally, the study population comprised of 58 patients, in which PTBD was performed with an internal-external drainage tube. After all patients underwent initial PTBD, the $^{125}$I stranded seeds treatment strategy was recommended by the attending physician. If the patient agreed to the recommendation, $^{125}$I stranded seeds were administered. Patients who refused $^{125}$I stranded seeds were treated with PTBD alone. Finally, 20 of the 58 patients who underwent PTBD combined with $^{125}$I stranded seeds were included in group A. A total of 38 patients were comprised in group B, who were treated with PTBD alone.

Internal-external drainage tubes from Create Medic Co. (Kanagawa, Japan) were used. Iodine-$^{125}$S seeds (4.5 mm × 0.8 mm, 1.70 cm effective functional diameter; 0.58 mci activity with a half-life of 59.6 days and 27.4-35.5 keV of radiation energy) from Shanghai GMS Pharmaceutical Co., Ltd. (China) were also used.

**Procedure**

All procedures were performed by a highly experienced surgeon with an expert knowledge of both PTBD and PTBD combined with $^{125}$I stranded seeds procedures. CT, MRI, or ultrasound confirmed the planned puncture pathway. An epigastic approach was employed for punctures of the left biliary system, whilst a right-sided intercostal approach was employed for punctures of the right biliary system to guarantee the stability of drainage catheter and to reduce the risk of bleeding. First, a local anesthetic was injected (5-10 ml of xylocaine), using a 22-gauge spinal needle positioned subcutaneously and up to the liver capsule. The intrahepatic biliary duct (right or left) was punctured with a 22-gauge Chiba needle using a micropuncture kit (Cook Medical Inc., Bloomington, USA) under ultrasound guidance. A micro guidewire was passed and advanced as close as possible to the stenosis/occlusion under fluoroscopic guidance. The Chiba needle was exchanged for a 4-Fr coaxial dilator, and a working cannula was positioned. A guidewire and a 5-Fr cobra catheter (Terumo, Tokyo, Japan) crossed the stenosis/occlusion with different tip morphologies, according to anatomical findings. Finally, a unilateral (right or left duct involvement or low bile duct obstruction) or bilateral (hilar hepatic duct lesions involving both left and right hepatic ducts) drainage tubes (Cook Medical Inc., Bloomington, USA) were placed across the stenosis/occlusion, with the distal tip reaching the duodenum.

Seven days post-implantation of the drainage tube, group A underwent implantation of $^{125}$I stranded seeds. To manufacture the $^{125}$I stranded seeds, a flexible stiffening cannula (Create Medic Co., Kanagawa, Japan) with a sealed tip was utilized. The $^{125}$I seeds were arranged in the cannula to prepare the seed strand. The $^{125}$I stranded seeds were then sent through an internal-external drainage tube under fluoroscopic surveillance to allow appropriate placement at the site of obstruction. None of these procedures were performed under anesthesis. The length of $^{125}$I stranded seeds was designed to be slightly longer than the obstruction to ensure full exposure (Figure 1). Finally, the internal-external drainage tube and the end of the $^{125}$I stranded seeds were fixed onto the skin surface. Protective radiological procedures were performed according to the criteria recommended by the International Commission on Radiological Protection (ICRP) [9]. Exposure was minimized and protective vests were worn.

**Follow-up**

Patients were followed up after the procedure and subsequent factors were recorded: treatment-related toxicity, bilirubin and tumor markers, biliary obstruction-free time, and survival time. Treatment-related toxicity was assessed according to the National Cancer Institute’s Common Terminology Criteria for adverse events (CTCAE, version 4.0) [6]. Imaging and laboratory tests were performed preoperatively and at week 1, and 1- and 3-months post-operation. Drainage tube occlusion was considered to be present in patients who developed symptoms of obstructive jaundice again, and these patients were followed by cholangiopancreatography under fluoroscopic guidance. Overall survival (OS) was calculated from the day of drainage tube implantation to the day of death.

**Statistical analysis**

Categorical data were described by number (%), while continuous data were expressed as mean ± standard deviation (SD), or median with either minimum or maximum. Categorical data were compared via Pearson χ² test or Fisher’s exact test, if more than 20% of cells with an expected count of less than five were observed. Kolmogorov-Smirnov’s and Shapiro-Wilk tests were used to determine whether the continuous variables were normally distributed. Variables conforming to a normal distribution were compared via Student’s t-test; otherwise, Mann-Whitney U test was used for comparison. Kaplan-Meier method was used to plot the biliary obstruction-free time and survival curves, while the significance between these curves was assessed through the log-rank test. P-values < 0.05 were considered statistically significant. SPSS v23.0 (IBM Corp.) was used for all statistical analyses.

**Results**

A total of 58 patients were included in this study after application of appropriate exclusion criteria. The general demographic information of patients is provided in Table 1.
The technical success rate in the two groups was 100%. Treatment-related toxicity did not significantly differ between the two groups ($p > 0.05$) (Table 2). Grade 1/2 adverse events (AEs) were relatively mild and alleviated spontaneously or after conservative management. We observed an improvement of grade 3/4 AEs after medication for biliary tract infections increased serum amylase and cardio-biliary reflexes (triggered by pain in the gallbladder via autonomic vagal innervations). Skin leaks, liver abscesses (through direct contact of infected biliary tract), and catheter migration were independently managed by replacement of drainage tubes, percutaneous puncture, and drainage tube adjustments. In addition, $^{125}$I stranded seeds migration and $^{125}$I seeds dislocation did not appear during follow-up in group A. In all patients, the cause of death was due to tumor progression.

In group A, out of 20 patients, 13 underwent unilateral implantation with internal-external drainage tubes, and 7 patients underwent bilateral implantation with internal-external drainage tubes. An average of 21.4 ±13.0 (range, 10-40) $^{125}$I seeds were implanted, with a mean radionuclide activity of 12.4 mCi ±7.5 (range, 7.0-23.2 mCi) per patient. Estimated total radiation doses were approximately 50-80 Gy, as determined at specific dose reference points calculated using the treatment planning system (TPS; University of Beijing Aeronautics and Astronautics, Beijing, China). The average procedure time for the implantation of $^{125}$I stranded seeds for every patient was 31.5 ±6.5 min (range, 25.0-45.0 min). In group B, out of 38 patients, 25 underwent unilateral implantation with internal-external drainage tubes, and 13 patients underwent bilateral implantation with internal-external drainage tubes. The differences in total bilirubin, direct bilirubin, and indirect bilirubin levels between the two groups were not significant at preoperative time points ($p = 0.857$, $p = 0.719$, and $p = 0.870$, respectively), and at the 1-week post-operative time point, these differences were also not significant ($p = 0.259$, $p = 0.395$, and $p = 0.145$, respectively). However, in 1-month ($p = 0.012$, $p = 0.005$, and $p = 0.049$, respectively) and 3-month post-operatively, group A was lower than group B ($p < 0.001$, $p = 0.001$, and $p = 0.001$, respectively), as shown in Table 3. The differences in carbohydrolipid metabolism were significant between the two groups at post-operative time points.

![Fig. 1. A 51-year-old male with cholangiocarcinoma, Bismuth-Corlette type III. Preoperative MRI (A) showed intrahepatic bile duct dilation. Percutaneous transhepatic biliary drainage (PTBD) was performed with one internal-external drainage tube under fluoroscopic monitoring. Imaging showed (B) substantial narrowing at the hepatic duct. One week later, two of the $^{125}$I stranded seeds were placed through the internal-external drainage tube (C). Three months after operation, CT showed gross ascites causing scalloping of liver margins, without intrahepatic bile duct dilation (D).](image-url)
drate antigen 19-9 (CA19-9), cancer antigen 125 (CA125), and carcino-embryonic antigen (CEA) levels between the two groups were not significant at the preoperative time point ($p = 0.229$, $p = 0.116$, and $p = 0.273$, respectively), nor were they significant at the 3-month post-operative time point ($p = 0.159$, $p = 0.342$, and $p = 0.306$, respectively), as presented in Table 4. Median biliary obstruction-free time was significantly different between groups ($p < 0.001$), with 7.0 months [95%CI: 5.2-8.8 months] for group A and 5.0 months [95%CI: 4.4-5.6 months] for group B (Figure 2). Median patient survival time differed significantly ($p = 0.001$) and was 9.0 months [95%CI: 8.3-9.7 months] for group A and 6.0 months [95%CI: 5.2-6.8 months] for group B (Figure 3).
**Table 3.** Changes in the preoperative and post-operative bilirubin levels in the two groups of patients

| Parameter | Group A (n = 20) | Group B (n = 38) | P-value |
|-----------|------------------|------------------|---------|
| Preoperative |                  |                  |         |
| TBIL (mg/dl) | 237.30 (55.50-518.50) | 204.75 (68.20-968.80) | 0.857   |
| DBIL (mg/dl) | 118.25 (26.10-343.70) | 92.75 (31.10-432.30) | 0.719   |
| IBIL (mg/dl) | 118.10 (27.10-219.70) | 112.65 (19.70-536.50) | 0.870   |
| 1-week follow-up |                  |                  |         |
| TBIL (mg/dl) | 115.70 (22.50-251.90) | 148.10 (29.60-723.00) | 0.259   |
| DBIL (mg/dl) | 58.85 (10.70-138.40) | 74.65 (13.50-437.90) | 0.395   |
| IBIL (mg/dl) | 55.05 (11.80-126.90) | 75.29 (16.10-285.10) | 0.145   |
| 1-month follow-up |                  |                  |         |
| TBIL (mg/dl) | 50.30 (16.40-102.80) | 75.90 (13.50-536.50) | 0.012*  |
| DBIL (mg/dl) | 25.75 (6.40-52.70) | 42.20 (4.60-432.30) | 0.005*  |
| IBIL (mg/dl) | 21.15 (10.00-54.20) | 34.95 (8.90-94.20) | 0.049*  |
| 3-month follow-up |                  |                  |         |
| TBIL (mg/dl) | 48.40 (23.00-103.00) | 77.75 (24.00-428.00) | < 0.001* |
| DBIL (mg/dl) | 20.50 (9.00-70.00) | 35.30 (5.00-219.00) | 0.001*  |
| IBIL (mg/dl) | 25.25 (8.00-54.00) | 44.60 (14.00-209.00) | 0.001*  |

Data are presented as median (minimum-maximum), TBIL – total bilirubin, DBIL – direct bilirubin, IBIL – indirect bilirubin, *statistically significant difference

**Table 4.** Comparison of tumor marker levels in the two groups before and after the operation

| Parameter | Group A (n = 20) | Group B (n = 38) | P-value |
|-----------|------------------|------------------|---------|
| Preoperative |                  |                  |         |
| CA19-9 (U/ml) | 88.90 (0.60-1000.00) | 125.35 (0.60-1011.00) | 0.229   |
| CA125 (U/ml) | 26.05 (2.10-1424.00) | 33.30 (17.20-908.00) | 0.116   |
| CEA (ng/ml) | 6.20 (0.40-408.30) | 9.10 (0.40-88.20) | 0.273   |
| 3-months follow-up |                  |                  |         |
| CA19-9 (U/ml) | 50.95 (1.00-1000.00) | 150.65 (2.0-1024.00) | 0.159   |
| CA125 (U/ml) | 33.05 (1.90-1406.00) | 38.30 (11.60-5000.00) | 0.342   |
| CEA (ng/ml) | 7.40 (0.50-163.60) | 7.10 (1.00-132.90) | 0.306   |

Data are presented as median (minimum-maximum), CEA – carcino-embryonic antigen, CA19-9 – carbohydrate antigen 19-9, CA125 – cancer antigen 125

**Discussion**

Quality of life and survival are often poor in those patients with malignant obstructions of the bile duct occurring due to tumors of the pancreas, gall bladder, bile duct, and liver [1,10]. If they do not receive an aggressive treatment, the median survival time is 185 days [11]. Radical surgery is the main therapy for MBO, but due to the complexity of the anatomic structure of the bile duct, and the fact that most patients present at late stages, the majority of patients lose the opportunity for surgery [12]. Thus, the selection of the most appropriate treatment approach for these patients is critically important.

In the past, non-surgical treatments such as PTBD or stent implantation have been employed as a palliative approach to improve bile drainage [13,14]. The use of these approaches is, however, accompanied by a risk of occlusion and is limited in its ability to inhibit tumor growth [15,16]. Radiofrequency ablation (RFA) is currently the most preferred approach to be employed as a first-line palliative intervention in those individuals unable to undergo tumor resection [17]. But when the liver tumor or cholangiocarcinoma that is the source of this obstruction is near the hepatic hilum, it is associated with more complications including infections, peritonitis of the bile duct, and even fatal biliary chest fistulae. Therefore, in these patients, RFA is a less viable treatment option, and other
alternatives must be investigated [18]. Previous studies suggest that radio-chemotherapy can effectively treat MBO caused by biliary tract cancers. Chemotherapy can control systemic disease and allows the local effects of radiotherapy to translate into longer survival rates. However, survival benefits are only observed in non-metastatic disease, whilst those with metastatic disease show no benefits [19]. In addition, only a small number of patients received chemotherapy during follow-up due to their poor status or refusal of treatment.

In recent years, brachytherapy has been widely utilized for tumor treatment. It is performed by implanting radioactive sources either directly into the tumor tissue (interstitial brachytherapy) or into hollow organs (intracavitary radiotherapy). Results to date suggest that it is possible to achieve significant efficacy when using this approach to treat portal vein tumor emboli, prostate carcinomas, lung cancer, and MBO in particular [8,20]. Compared to intracavitary radiotherapy, interstitial brachytherapy is restricted for MBO. Due to the location and morphology of the lesions, a uniform distribution of $^{125}$I seeds was difficult to achieve at the site of lesion, which may impact its therapeutic effects. Secondly, patients who underwent percutaneous puncture operations were at higher risk. Thirdly, due to operator experience and skills limitations, only interstitial brachytherapy was performed in some centers [13,21,22]. However, intracavitary radiotherapy was feasible due to its minimally invasive technology and ease of manipulation [23]. For MBO, this method offers many advantages. Firstly, the radioactive source is small in size, permitting close proximity to the biliary duct. Secondly, this approach delivers high doses of radiation to localized tumors with limited systemic side effects. Thirdly, this approach represents a form of conformal radiotherapy that is associated with improved accuracy because of patient movement [24]. The mainstay treatment method of intracavitary radiotherapy consists of $^{125}$I stranded seeds and irradiation stents, all of which show efficacy. Unfortunately, obvious disadvantages exist for related irradiation stents, particularly when stent dysfunction is impossible to avoid. The exact causes of stent dysfunction were unclear. In addition, irradiation stents cannot be immediately withdrawn in any instance, as intracavitary brachytherapy-related complications can occur [6,24].

In our department, 58 patients diagnosed with MBO were enrolled in this study. In group A, 20 patients underwent PTBD combined with $^{125}$I stranded seeds, whereas in group B, 38 patients underwent simple PTBD. Technical success was achieved in all patients. Post-operation, the observed toxicities in the two groups showed no significant differences. Grade 1/2 AEs alleviated spontaneously or after conservative management. Grade 3/4 AEs including biliary tract infections, increased serum amylase, and cardio-biliary reflexes improved after medication. Skin leaks, liver abscesses, and catheter migration were independently managed by replacement of drainage tubes, percutaneous puncture, and drainage tube adjustments. In addition, $^{125}$I stranded seeds migration and $^{125}$I seeds dislocation did not appear during follow-up in group A. Iodine-125 is a low-energy radioisotope that is sufficient to provide a robust local radiation dose and good curative effect while causing minimal extraneous damage. This was a result of the effective range of $^{125}$I seeds being ~1.7 cm, such that surrounding normal tissue only received ≤ 25% of radioactive dose received by tumor cells [14,25].

The increased bilirubin observed after PTBD may be due to tumor ingrowth, tissue hyperplasia, sludge forma-

Fig. 2. The biliary obstruction-free time in group A and group B demonstrated that group A had a significantly better biliary obstruction-free time ($p < 0.001$)

Fig. 3. The survival time in group A and group B indicated that group A had a significantly better survival time ($p = 0.001$)
tion, or secondary biliary cirrhosis [14,26]. The observed reduction in bilirubin in group A was more pronounced than group B, with the likely explanation being that the patients in group A had undergone implantation with $^{125}\text{I}$ seeds. This implantation provided sustained localized irradiation to inhibit tumor growth and tissue hyperplasia, achieving long-term maintenance of normal bilirubin levels [14]. The excretion of bile was not itself affected by the $^{125}\text{I}$ stranded seeds.

The term "tumor marker" refers to the production of bioactive substances by malignant tumor cells that are then released into the blood. Serum levels of tumor markers can assist tumor diagnosis and evaluation of therapeutic effects of treatment [27,28]. In this study, preoperative and 3-month post-operative tumor marker levels did not significantly differ between the groups. There are several possible explanations for these findings. First, in group A, after $^{125}\text{I}$ stranded seed implantation, tumor cells sustain damage, and tumor degradation leads to a release of tumor markers into the blood [29], which could be another possible explanation is the delay in achieving steady-state levels following $^{125}\text{I}$ seed treatment [30]. Thus, in this study, no differences in the tumor marker levels between the two groups of patients were observed.

The median biliary obstruction-free time was 7.0 months for group A and 5.0 months for group B ($p < 0.001$). In group A, continuous low energy intracavitary brachytherapy can inhibit tumor mitosis, causing the tumor cells to remain in the G2 phase, resulting in eventual tumor cell killing by radiation. This approach can prevent tumor growth into the lumen of internal-external drainage tube, thereby reducing the risk of internal-external drainage tube stenosis or occlusion, as compared to the drainage alone [31,32]. Due to the long biliary obstruction-free time, this approach also reduces the frequency, at which patients undergo an exchange of internal-external drainage tubes and hospital stay, in addition to the cost of treatment.

The median survival time was 9.0 months for group A and 6.0 months for group B ($p = 0.001$). In addition, the survival times in group A showed a promising outcome compared to conventional drainage alone, as observed by Zhang et al. [12]. In group A, the $^{125}\text{I}$ stranded seeds were used as the radioactive source of intracavitary brachytherapy for the treatment of MBO. Iodine-$^{125}$ is a synthetic radioisotope of iodine allowing for the delivery of γ-ray radiation using radioactive seeds. Through γ-ray-mediated induction of tumor cell cycle arrest and inhibition of tumor angiogenesis, the goal of suppressing bile duct endothelial hyperplasia and disrupting the growth of cancerous cells are possible to achieve [33,34,35,36]. In addition, $^{125}\text{I}$ seeds deliver sustained irradiation to the tumor and can further oxygenize hypoxic cells, causing the tumor to become more sensitive to intracavitary brachytherapy, thus enhancing treatment efficacy [14]. Additionally, $^{125}\text{I}$ stranded seeds implantation offers the advantage of extended period of remission for those suffering from obstructive jaundice, thereby improving patient liver function and performance, delaying disease progression, and prolonging overall survival [31]. Moreover, the $^{125}\text{I}$ stranded seeds can be exchanged to further control tumor growth [36]. As such, a combination of drainage and $^{125}\text{I}$ stranded seed implantation compared to drainage alone can prolong survival times in patients with MBO.

This study has several limitations. Firstly, the sample size was not large enough to obtain a powerful statistical conclusion regarding the biliary obstruction-free period or overall survival. Due to this limited sample size, results may be influenced by the population distribution of the two groups in a manner unrelated to the $^{125}\text{I}$ stranded seeds themselves. Secondly, a prospective, randomized, multicenter study is needed to clarify the effectiveness of $^{125}\text{I}$ stranded seeds for the treatment of malignant biliary obstruction. Thirdly, a skin surface dosimeter was not employed after $^{125}\text{I}$ stranded seed placement; therefore, the precise radiation dose delivered to every patient remain unknown.

Conclusions

In summary, intracavitary brachytherapy may offer benefits to prolong the survival of patients with MBO. Iodine-$^{125}$ stranded seeds can be implanted along the internal-external drainage tube inserted at the site of a given lesion through a simple operation. It can more effectively restrain the proliferation of endothelial cells in the bile duct and disrupt the growth of cancerous cells. This approach is therefore worthy of further investigation and utilization in clinical practice.

Disclosure

The authors report no conflict of interest.

References

1. Chandrashekhara SM, Gamanagatti S, Singh A et al. Current status of percutaneous transhepatic biliary drainage in palliation of malignant obstructive jaundice: a review. Indian J Palliat Care 2016; 22: 378-387.
2. Miura S, Kanno A, Masamune A et al. Risk factors for recurrent biliary obstruction following placement of self-expandable metallic stents in patients with malignant perihilar biliary stricture. Endoscopy 2016; 48: 536-545.
3. Tsetis D, Krokidis M, Negru D et al. Malignant biliary obstruction: the current role of interventional radiology. Ann Gastroenterol 2016; 29: 33-36.
4. Zorrón Cheng Tao Pu L, Singh R, Kuan Loong C et al. Malignant biliary obstruction: evidence for best practice. Gastroenterol Res Pract 2016; 2016: 3296801.
5. Rerknimitr R, Aungsuvatcharakon P, Ratanachuk-ek T et al. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J Gastroenterol Hepatol 2013; 28: 593-607.
6. Jain S, Kataria T, Bisht SS et al. Malignant obstructive jaundice – brachytherapy as a tool for palliation. J Contemp Brachytherapy 2013; 5: 83-88.
7. Mensah ET, Martin J, Topazian M. Radiofrequency ablation for biliary malignancies. Curr Opin Gastroenterol 2016; 32: 238-243.
8. Li S, He X, Dang L et al. Efficacy of $^{125}\text{I}$ versus non-$^{125}\text{I}$ combined with transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma with obstructive jaundice. Dig Dis Sci 2018; 63: 321-328.
9. Zhu HD, Guo JH, Huang M et al. Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial. J Hepatol 2018; 68: 970-977.

10. Seok Nam H, Heon Kang D, Wook Kim H et al. Efficacy and safety of limited endoscopic sphincterotomy before self-expandable metal stent insertion for malignant biliary obstruction. World J Gastroenterol 2017; 23: 1627-1636.

11. Zhang GY, Li WT, Peng WJ et al. Clinical outcomes and prediction of survival following percutaneous biliary drainage for malignant obstructive jaundice. Oncol Lett 2014; 7: 1185-1190.

12. Sutter CM, Ryu RK. Percutaneous management of malignant biliary obstruction. Tech Vasc Interv Radiol 2015; 18: 218-226.

13. Qin LX, Tang ZY. Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis. World J Gastroenterol 2003; 9: 385-391.

14. Bigot P, Buchanan GM, Hanny A et al. Rupture of hepatocellular carcinoma into the biliary system with resulting bile duct thrombosis: report of two cases. Case Rep Gastroenterol 2007; 1: 123-129.

15. Ma J, Luo J, Gu J et al. Malignant obstructive jaundice treated with intraluminal placement of Iodine-125 seed strands and metal stents: An analysis of long-term outcomes and prognostic features. Brachytherapy 2018; 17: 689-695.

16. Jin H, Pang Q, Liu H et al. Prognostic value of inflammation-based markers in patients with recurrent malignant obstructive jaundice treated by reimplantation of biliary metal stents: A retrospective observational study. Medicine (Baltimore) 2017; 96: e5895.

17. Shindoh J. Ablative therapies for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017; 6: 2-6.

18. Marchal F, Elias D, Rauch P et al. Prevention of biliary lesions that may occur during radiofrequency ablation of the liver. Ann Surg 2006; 243: 82-88.

19. Pollom EL, Alagappan M, Park LS et al. Does radiotherapy still have a role in unresected biliary tract cancer? Cancer Med 2017; 6: 129-141.

20. Hsiao Y, Hsu B, Wang H et al. Implementation of computed tomography-guided Iodine-125 seeds in combination with chemotherapy for the treatment of stage III non-small cell lung cancer. J Contemp Brachytherapy 2017; 9: 527-534.

21. Yang B, Guo WH, Lan T et al. CT-guided 125I seed implantation for inoperable retroperitoneal sarcoma: A technique for delivery of local tumor brachytherapy. Exp Ther Med 2016; 12: 3843-3850.

22. Chen W, Fang XM, Wang X et al. Preliminary clinical application of integrated 125I seeds stents in the therapy of malignant lower biliary tract obstruction. J Xray Sci Technol 2018; 26: 865-875.

23. Wang Y, Lu J, Guo JH et al. A novel tracheobronchial stent loaded with 125I seeds in patients with malignant airway obstruction compared to a conventional stent: a prospective randomized controlled study. EBioMedicine 2018; 33: 269-275.

24. Dechao J, Han X, Yanli W et al. Y-configured metallic stent combined with 125I seed strands cavity brachytherapy for a patient with type IV Klatskin tumor. J Contemp Brachytherapy 2016; 8: 356-360.

25. Li J, Zhang L, Xie Q et al. Comparison of clinical efficacy and complications of 125I seed brachytherapy and stereotactic body radiation therapy for recurrent pulmonary metastases from colorectal carcinoma. J Contemp Brachytherapy 2018; 10: 360-364.

26. Gamanagatti S, Singh T, Sharma R et al. Unilobar versus bilobar biliary drainage: effect on quality of life and bilirubin level reduction. Indian J Palliat Care 2016; 22: 50-62.

27. Rückert F, Pilarsky C, Grützmann R. Serum tumor markers in pancreatic cancer – recent discoveries. Cancers (Basel) 2010; 2: 1107-1124.

28. Holdenrieder S, Pagliaro L, Morgenstern D et al. Clinically meaningful use of blood tumor markers in oncology. Biomed Res Int 2016; 2016: 59795269.

29. Bartsch R, Wenzel C, Pluschig U et al. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment. BMC Cancer 2006; 6: 81.

30. Robertson JFR, Erikstein B, Osborne KC et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet 2004; 43: 529-538.

31. Zhou YM, Feng X, Zhou BC et al. Evaluation of therapeutic effects of 125I particles brachytherapy for recurrent bladder cancer. Oncol Lett 2018; 15: 3453-3457.

32. Verellen D, De Ridder M, Linhout N et al. Innovations in image-guided radiotherapy. Nat Rev Cancer 2007; 7: 949-960.

33. Wang T, Liu S, Zheng YB et al. Clinical study on using 125I seeds articles combined with biliary stent implantation in the treatment of malignant obstructive jaundice. Anticancer Res 2017; 37: 4649-4653.

34. Guo Y, Liu Y, Lu Z et al. Obstructive component analysis of radioactive stents and common plastic stents in the bile duct. Eur J Gastroenterol Hepatol 2014; 26: 795-802.

35. Zhang W, Yang ZQ, Shi HB et al. Placement of 125I seed strands and stents for a type IV Klatskin tumor. World J Gastroenterol 2015; 21: 373-376.

36. Hasimun A, Gu JP, Ji WZ et al. Comparative study of percutaneous transhepatic biliary stent placement with or without Iodine-125 seeds for treating patients with malignant biliary obstruction. J Vasc Interv Radiol 2017; 28: 583-593.